ClinConnect ClinConnect Logo
Search / Trial NCT01708655

Sweat Evaporimeter Measurement

Launched by UNIVERSITY OF COLORADO, DENVER · Oct 16, 2012

Trial Information

Current as of July 16, 2025

Completed

Keywords

Cystic Fibrosis Sweat Evaporimeter

ClinConnect Summary

Preliminary data show that following β-adrenergic stimulation, evaporimetry can reliably measure sweat secretion that is: highly reproducible in healthy controls; reduced by 50% in CF obligate heterozygotes; and absent in CF patients carrying severe mutations on both alleles. Further, test- retest experiments suggest good intra-individual reliability. All these features satisfy the required criteria for a biomarker assay that is capable of assessing small increments in CFTR function in vivo in clinical trials designed to assess the effectiveness of correctors and potentiators of CFTR channe...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female ages 18 years and older.
  • 2. Subject with or without confirmed diagnosis of CF.
  • 3. Written informed consent obtained from subject.
  • Exclusion Criteria:
  • 1. Patients who are participating in clinical trials evaluating the safety, efficacy or clinical outcome of drugs that may alter the CFTR Cl channel function will be excluded.
  • 2. Any subject with a known hypersensitivity to any agonist used in the study or subjects receiving any drug (e.g. theophylline, antihypertensive agent) that might interfere with the investigations.
  • 3. Subjects with active dermatitis or other chronic skin condition such as psoriasis or a strong allergic history.
  • 4. Patients with a history of cardiac disease (including arrhythmias or hypertrophic obstructive cardiomyopathy).
  • 5. CF patients with severe malnutrition (BMI\<18 kg/m2).
  • 6. CF patients with severe lung disease (FEV1\<25%).
  • 7. Subject who has been treated for pulmonary exacerbation or other acute illness within one week of the study procedure.
  • 8. Any medical condition that, in the opinion of the investigator, will interfere with accurate conduct of the study.
  • 9. Subjects who are pregnant or lactating.
  • 10. Subject who is not able to stop inhalation therapy of β -adrenergic drugs 12 hrs before starting each test.

About University Of Colorado, Denver

The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.

Locations

Aurora, Colorado, United States

Patients applied

0 patients applied

Trial Officials

Frank J Accurso, MD

Principal Investigator

Children's Hospital Colorado

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials